NCT06206733 - ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | Biotech Hunter

Enrollment

780

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions

Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma

Interventions

DRUG

ASKB589

ASKB589 will be administered as a minimum 3-hour IV infusion

DRUG

Oxaliplatin

Oxaliplatin will be administered as a minimum 2-hour IV infusion

DRUG

Capecitabine

Capecitabine will be administered orally twice daily (bid).

DRUG

Tislelizumab

Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.

DRUG

Placebo

Placebo will be administered as a minimum 3-hour IV infusion

Trial Locations (1)

RECRUITING

Beijing cancer hospital, Beijing